PMN Key Statistics, Chart & Performance
The current stock price of PMN is 8.59 USD. In the past month the price decreased by -2.72%. In the past year, price decreased by -70.14%.
PMN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.19B | ||
| AMGN | AMGEN INC | 15.56 | 183.30B | ||
| GILD | GILEAD SCIENCES INC | 15.16 | 154.03B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.82 | 122.54B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.02 | 85.23B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 825.8 | 55.64B | ||
| INSM | INSMED INC | N/A | 37.42B | ||
| NTRA | NATERA INC | N/A | 35.14B | ||
| BIIB | BIOGEN INC | 11.09 | 27.23B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.1 | 21.71B | ||
| INCY | INCYTE CORP | 17.29 | 21.79B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.28B |
Related stock screener links
About PMN
Company Profile
ProMIS Neurosciences Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2017-04-03. ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. The company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Company Info
PROMIS NEUROSCIENCES INC
Suite 200, 1920 Yonge Street
TORONTO ONTARIO CA
Employees: 6
Phone: 14168476898
PROMIS NEUROSCIENCES INC / PMN FAQ
What does PMN do?
ProMIS Neurosciences Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2017-04-03. ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. The company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Can you provide the latest stock price for PROMIS NEUROSCIENCES INC?
The current stock price of PMN is 8.59 USD. The price increased by 11.7% in the last trading session.
Does PMN stock pay dividends?
PMN does not pay a dividend.
How is the ChartMill rating for PROMIS NEUROSCIENCES INC?
PMN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is PROMIS NEUROSCIENCES INC (PMN) stock traded?
PMN stock is listed on the Nasdaq exchange.
PMN Technical Analysis
PMN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PMN Forecast & Estimates
8 analysts have analysed PMN and the average price target is 137.06 USD. This implies a price increase of 1495.6% is expected in the next year compared to the current price of 8.59.